Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
Lise M. van Wijk, Andreea B. Nilas, Harry Vrieling, et al.
Expert Review of Molecular Diagnostics (2021) Vol. 22, Iss. 2, pp. 185-199
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Exploiting replication gaps for cancer therapy
Ke Cong, Sharon B. Cantor
Molecular Cell (2022) Vol. 82, Iss. 13, pp. 2363-2369
Open Access | Times Cited: 67
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
Peng Yuan, Nan Ma, Binghe Xu
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2774-2792
Open Access | Times Cited: 6
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Sanna Pikkusaari, Manuela Tumiati, Anni Virtanen, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3110-3123
Open Access | Times Cited: 16
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
Łukasz Biegała, Arkadiusz Gajek, Agnieszka Marczak, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1038-1038
Open Access | Times Cited: 16
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Lorena Incorvaia, Alessandro Perez, Cláudia Marchetti, et al.
Cancer Treatment Reviews (2023) Vol. 121, pp. 102650-102650
Open Access | Times Cited: 16
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
Loïck Galland, Nicolas Roussot, Isabelle Desmoulins, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1299-1299
Open Access | Times Cited: 14
Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity
Lea Milling Korsholm, Maj K. Kjeldsen, Lorenzo Perino, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 5
Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R. Fonte, Sabino Strippoli, Marianna Garofoli, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 12
Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in BRCA1/2-Proficient Cancer Cells
Danyang Zhou, Wei Liu, Yanyan Zhang, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 958-958
Open Access
The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan
Kuo-Liang Chiu, Shou-Cheng Wang, Chia-Hsiang Li, et al.
Anticancer Research (2024) Vol. 44, Iss. 4, pp. 1409-1416
Open Access | Times Cited: 3
PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy
Sanat Kulkarni, N. Seneviratne, Çağla Tosun, et al.
DNA repair (2025), pp. 103830-103830
Open Access
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Giada Pinterpe, Fortuna Migliaccio, Chiara Ciccarese, et al.
Targeted Oncology (2025)
Closed Access
HR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy
Shinta Saito, Shingo Kato, Usaki Arai, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value
Chunying Zheng, Zhen Ren, Hongliang Chen, et al.
Experimental Cell Research (2022) Vol. 421, Iss. 2, pp. 113388-113388
Closed Access | Times Cited: 12
Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer
Sanat Kulkarni, Ketankumar Gajjar, Srinivasan Madhusudan
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
Rui Bi, Li Chen, Mei Huang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189221-189221
Open Access | Times Cited: 2
HR repair pathway plays a crucial role in maintaining neural stem cell fate under irradiation stress
Xiao Xu, Huanping An, Cheng Wu, et al.
Life Science Alliance (2023) Vol. 6, Iss. 8, pp. e202201802-e202201802
Open Access | Times Cited: 4
RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
Claire J.H. Kramer, Alba Llop‐Guevara, Elisa Yaniz‐Galende, et al.
The Journal of Pathology Clinical Research (2023) Vol. 9, Iss. 6, pp. 442-448
Open Access | Times Cited: 4
Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice
Kris G. Samsom, Linda J.W. Bosch, Luuk J. Schipper, et al.
Nature Protocols (2023) Vol. 19, Iss. 3, pp. 700-726
Closed Access | Times Cited: 4
Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis
Yen‐Yun Wang, Kuang‐Hung Cheng, Amos C. Hung, et al.
International Journal of Oncology (2023) Vol. 64, Iss. 2
Open Access | Times Cited: 3
Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead
Erica S. Tsang, Pamela N. Münster
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1509-1518
Open Access | Times Cited: 5
Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue
Lise M. van Wijk, Sylvia Vermeulen, Natalja T. ter Haar, et al.
Breast Cancer Research and Treatment (2023) Vol. 202, Iss. 3, pp. 607-616
Open Access | Times Cited: 2
Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines
Anne E. Dodson, Sol Shenker, Pamela Sullivan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Contribution of Radiation Sensitive Protein 51 Genotypes to Pterygium Risk in a Taiwanese Population
Ning‐Yi Hsia, Pei-Shin Hu, Chin-Liang Chuang, et al.
In Vivo (2024) Vol. 38, Iss. 5, pp. 2197-2204
Open Access
Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer
Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top